nach oben

International Journal of Clinical Oncology

Erschienen in:

09.05.2019 | Original Article

Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma

verfasst von: Kazuki Takasaki, Morikazu Miyamoto, Masashi Takano, Hiroaki Soyama, Tadashi Aoyama, Hiroko Matsuura, Hideki Iwahashi, Hiroki Ishibashi, Takahiro Sakamoto, Kenichi Furuya

Erschienen in: International Journal of Clinical Oncology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to examine the clinical significance and risk factors of thromboembolic events (TEEs) in patients with ovarian carcinoma.

Methods

Patients with ovarian carcinoma treated at our hospital between 2000 and 2017 were identified. The risk factors of TEEs, including venous TEEs and arterial TEEs, and the association between TEEs and prognosis were investigated. Patients with TEEs were classified into two groups: those with severe TEEs, defined as patients who required urgent treatment for deep vein thrombosis, massive pulmonary embolism, acute myocardial infarction, and symptomatic cerebral infarction, and those with mild TEEs. The risk factors of severe TEEs and the association between severe TEEs and prognosis were investigated.

Results

A total of 369 patients were enrolled. Among them, 53 patients (14.4%) were complicated with TEEs. Clear cell carcinoma (CCC) was a greater risk factor of TEEs than serous carcinoma (hazard ratio [HR] = 2.81, p = 0.03). In multivariate analysis for survival, TEEs were a prognostic factor of poor progression-free survival (PFS; HR = 2.90, p < 0.01) and overall survival (OS; HR = 2.89, p < 0.01). Among 53 patients with TEEs, 17 (32.1%) developed severe TEEs. CCC was strongly associated with severe TEEs (HR = 42.6, p = 0.02). Multivariate analysis for survival demonstrated that severe TEEs were a risk factor of worse PFS (HR = 4.34, p < 0.01) and OS (HR = 3.30, p = 0.03).

Conclusion

TEEs induced poor prognosis and was associated with CCC. A standard treatment for CCC should be included in the strategy of TEEs.

Baldwin LA, Huang B, Miller RW et al (2012) Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120:612–618CrossRefPubMed

Burgers A, Schmalfeldt B (2011) Ovarian cancer diagnosis and treatment. Dtsch Arztebl Int 108:635–641

Pujade-Lauraine E, Alexander J (2011) Update of randomized trials in recurrent disease. Ann Oncol Suppl 8:61–64

Coleman RL, Monk BJ, Sood AK et al (2013) Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10:211–224CrossRefPubMedPubMedCentral

Naumann RW, Coleman RL (2011) Management strategies for recurrent platinum-resistant ovarian cancer. Drugs 71:1397–1412CrossRefPubMed

Li M, Li H, Liu F et al (2017) Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res 10:9CrossRefPubMedPubMedCentral

Fujiwara K, Shintani D, Nishikawa T (2016) Clear-cell carcinoma of the ovary. Ann Oncol Suppl 1:50–52. https://doi.org/10.1093/annonc/mdw086 CrossRef

Miyamoto M, Takano M, Goto T et al (2013) Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review. J Gynecol Oncol 24:37–43CrossRefPubMedPubMedCentral

Friedlander ML, Russel K, Millis S et al (2016) Molecular profiling of clear cell ovarian cancers: identifying potential treatment targets for clinical trials. Int J Gynecol Cancer 26:648–654CrossRefPubMedPubMedCentral

10.

Tan DS, Miller RE, Kaye SB (2013) New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. Br J Cancer 108:1553–1559CrossRefPubMedPubMedCentral

11.

Sakurai M, Matsumoto M, Sakata A et al (2017) Expression of tissue factor in epithelial ovarian carcinoma is involved in the development of venous thromboembolism. Int J Gynecol Cancer 27:37–43CrossRefPubMed

12.

Metcalf RL, Fry DJ, Swindell R et al (2014) Thrombosis in ovarian cancer: a case control study. Br J Cancer 110:1118–1124CrossRefPubMedPubMedCentral

13.

Cohen JG, Prendergast E, Geddings JE et al (2017) Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. Gynecol Oncol 146:146–152CrossRefPubMed

14.

Ye S, Yang J, Cao D et al (2015) Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study. PLoS ONE 10:1–10

15.

Kuroda H, Mabuchi S, Shigeta N et al (2014) Recurrent cerebral infarctions in patient with ovarian cancer: a fatal case of Trousseau’s syndrome. Gynecol Obstet 4:1–4CrossRef

16.

Takano H, Nakajima K, Nagayoshi Y et al (2018) Clinical associations of Trousseau's syndrome associated with cerebral infarction and ovarian cancer. J Gynecol Oncol 29:67CrossRef

17.

Tateo S, Mereu L, Salamano S et al (2005) Ovarian cancer and venous thromboembolic risk. Gynecol Oncol 99:119–125CrossRefPubMed

18.

Greco PS, Bazzi AA, Mclean K et al (2017) Incidence and timing of thromboembolic events in patients with ovarian cancer undergoing neoadjuvant chemotherapy. Obstet Gynecol 129:979–985CrossRefPubMed

19.

Satoh T, Oki A, Uno K et al (2007) High incidence of silent venous thromboembolism before treatment in ovarian cancer. Br J Cancer 97:1053–1057CrossRefPubMedPubMedCentral

20.

Sorensen HT, Mellemkjaer L, Steffensen FH et al (1998) The risk of a diagnosis of cancer after deep vein thrombosis or pulmonary embolism. N Engl J Med 338:1169–1173CrossRefPubMed

21.

Naoi H, Hashimoto H, Kajimoto E et al (2013) Cerebral infarctions as manifestation of ovarian clear cell carcinoma: report of two cases and review of the literature. Int Canc Conf J 2:206–210CrossRef

22.

Yang CM, Hsieh MY, Lin L et al (2013) Acute myocardial infarction in association with occult ovarian cancer. Acta Cardiol Sin 29:102–106CrossRefPubMedPubMedCentral

23.

Prat J, FIGO Committee on Gunecologic Oncology (2015) FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. J Gynecol Oncol 26:87–89CrossRefPubMedPubMedCentral

24.

Ebina Y, Uchiyama M, Imafuki H et al (2018) Risk factors for deep venous thrombosis in women with ovarian cancer. Medicine (Baltimore) 97:1–6CrossRef

25.

Uno K, Homma S, Satoh T et al (2007) Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer 96:290–295CrossRefPubMedPubMedCentral

26.

Matsuo K, Hasegawa K, Yoshino K et al (2015) Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. Eur J Cancer 51:1978–1988CrossRefPubMed

27.

Koizume S, Miyagi Y (2015) Tissue factor-factor VII complex as a key regulator of ovarian cancer phenotypes. Biomarker Cancer 7:1–13

28.

Duan Z, Foster R, Bell DA et al (2006) Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12:5055–5063CrossRefPubMed

29.

Coward J, Kullbe H, Chakravarty P et al (2011) Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 17:6083–6096CrossRefPubMedPubMedCentral

30.

Lane D, Matte I, Rancourt C et al (2011) Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 11:210CrossRefPubMedPubMedCentral

31.

Yoshikawa T, Miyamoto M, Aoyama T et al (2018) JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. Oncol Lett 15:5772–5780PubMedPubMedCentral

32.

Yanaihara N, Hirata Y, Yamaguchi N et al (2015) Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog 55:832–841CrossRefPubMed

33.

Tetsche MS, Nørgaard M, Pedersen L et al (2006) Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer 6:189CrossRefPubMedPubMedCentral

34.

Einstein MH, Pritts EA, Hartenbach EM (2007) Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol 105:813–819CrossRefPubMed

35.

Miyamoto M, Takano M, Iwaya K et al (2014) X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary. Br J Cancer 110:2881–2886CrossRefPubMedPubMedCentral

36.

Miyamoto M, Takano M, Aoyama T et al (2017) Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas. J Gynecol Oncol 28:33CrossRef

37.

Chavan DM, Huang Z, Song K et al (2017) Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer. Medicine (Baltimore) 96:e7935CrossRef

38.

Matsuura Y, Robertson G, Marsden DE et al (2007) (2007) Thromboembolic complications in patients with clear cell carcinoma of the ovary. Gynecol Oncol 104:406–410CrossRefPubMed

39.

Kröger K, Weiland D, Ose C et al (2006) Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 17:297–303CrossRefPubMed

40.

De Martino RR, Goodney PP, Spangler EL et al (2012) Variation in thromboembolic complications among patients undergoing commonly performed cancer operations. J Vasc Surg 55:1035–1040CrossRefPubMedPubMedCentral

Titel: Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma
verfasst von: Kazuki Takasaki
Morikazu Miyamoto
Masashi Takano
Hiroaki Soyama
Tadashi Aoyama
Hiroko Matsuura
Hideki Iwahashi
Hiroki Ishibashi
Takahiro Sakamoto
Kenichi Furuya
Publikationsdatum: 09.05.2019
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 10/2019
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-019-01464-4

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma